FDA Crackdown on Off-Brand Ozempic Products Set to Take Effect, Threatening Supply and Access for Many
- The FDA set a May 22, 2025 deadline to stop sales of compounded off-brand semaglutide drugs like Ozempic and Wegovy in the U.S.
- This action follows prolonged shortages since 2022 and 1,000 reported adverse events linked to unapproved compounded GLP-1 medications lacking FDA approval.
- Novo Nordisk, the manufacturer of the semaglutide medications approved to treat diabetes and promote weight loss, has increased its legal efforts and marketing campaigns targeting companies that produce unauthorized versions of these drugs.
- Novo offers new patients a $300 discount on Wegovy, reducing the first month’s cost to $199 from a $1,349 list price, according to Executive VP Dave Moore.
- The crackdown may reduce cheaper alternatives, likely tightening supply and shifting patients back to high-cost, FDA-approved semaglutide treatments.
Insights by Ground AI
Does this summary seem wrong?
103 Articles
103 Articles
All
Left
10
Center
54
Right
8
Second Ashland weight loss clinic accused of administering non-FDA approved drugs
ASHLAND A weight loss clinic with multiple locations in Kentucky, including Ashland, is facing accusations of providing patients with non-FDA approved semaglutide — falsely advertising a compounded drug as safe by comparing it to Ozempic and other trending weight loss…
·Kentucky, United States
Read Full ArticleThese venomous lizards helped make Ozempic. Now 2 are at Saskatoon zoo
The Saskatoon Forestry Farm & Zoo is now home to a pair of Gila monsters, venomous lizards that live primarily in Arizona and Mexico. Their venom played a significant role in the development of drugs used to treat diabetes and obesity.
·Canada
Read Full ArticleCoverage Details
Total News Sources103
Leaning Left10Leaning Right8Center54Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
14%
C 75%
11%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage